Genomic Risk in Retroperitoneal Sarcoma

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Fox Chase Cancer Center
Study ID
NCT06436846
Status
Recruiting
Apply to this trial

Conditions

  • Retroperitoneal Liposarcoma
  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Biospecimen sample collection during standard-of-care surgery — OTHER
    Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.

Study Details

The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.

Key Dates

Start date
Mar 7, 2022
Status verified
May 2024
Primary completion
Jun 30, 2027
Completion
Aug 1, 2027

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Cohort 1
    The entire study is a singular cohort of patients with retroperitoneal liposarcoma (index or recurrent) who undergo surgical resection of their tumor.

Primary Outcome Measure

Presence of MDM2 amplification in "normal" retroperitoneal fat [ Time Frame: Through study completion, an average of 3 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111
Anthony Villano, MD
[email protected]
215-728-3686
Margaret vonMehren, MD (SUB_INVESTIGATOR)
Andres Correa, MD (SUB_INVESTIGATOR)
Jeffrey Farma, MD, FACS (SUB_INVESTIGATOR)
Stephanie Greco, MD, FACS (SUB_INVESTIGATOR)
Alexander Kutikov, MD, FACS (SUB_INVESTIGATOR)
Sanjay Reddy, MD, FACS (SUB_INVESTIGATOR)
Lori Rink, PhD (SUB_INVESTIGATOR)
Marc Smaldone, MD, MSHP, FACS (SUB_INVESTIGATOR)
Robert Uzzo, MD, MBA, FACS (SUB_INVESTIGATOR)
Rosalia Viterbo, MD, FACS (SUB_INVESTIGATOR)
Shuanzeng Wei, MD, PhD (SUB_INVESTIGATOR)
Johnathan Whetstine, PhD (SUB_INVESTIGATOR)
Margaret von Mehren, MD (SUB_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Fox Chase Cancer Center· Philadelphia, PA

Related Studies